Biotechnology stocks are a potential growth opportunity and safe haven

Underpinned by M&A activity and driven by urgent 'big pharma' demand for replacement products, large...

Underpinned by M&A activity and driven by urgent 'big pharma' demand for replacement products, large- and mid-cap biotechnology stocks offer solid, defensive growth potential. High barriers to entry, product innovation and historically cheap valuations only further enhance the proposition. With pharmaceutical companies struggling, investors are increasingly looking towards the biotech sector as an area of relative market safety. M&A activity is a prominent feature of the biotech sector, underpinning performance. One of the key drivers of this activity is the pharmaceutical 'patent cliff' ...